BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1940 related articles for article (PubMed ID: 28445469)

  • 1. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
    Abbosh C; Birkbak NJ; Wilson GA; Jamal-Hanjani M; Constantin T; Salari R; Le Quesne J; Moore DA; Veeriah S; Rosenthal R; Marafioti T; Kirkizlar E; Watkins TBK; McGranahan N; Ward S; Martinson L; Riley J; Fraioli F; Al Bakir M; Grönroos E; Zambrana F; Endozo R; Bi WL; Fennessy FM; Sponer N; Johnson D; Laycock J; Shafi S; Czyzewska-Khan J; Rowan A; Chambers T; Matthews N; Turajlic S; Hiley C; Lee SM; Forster MD; Ahmad T; Falzon M; Borg E; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Hafez D; Naik A; Ganguly A; Kareht S; Shah R; Joseph L; Marie Quinn A; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Oukrif D; Akarca AU; Hartley JA; Lowe HL; Lock S; Iles N; Bell H; Ngai Y; Elgar G; Szallasi Z; Schwarz RF; Herrero J; Stewart A; Quezada SA; Peggs KS; Van Loo P; Dive C; Lin CJ; Rabinowitz M; Aerts HJWL; Hackshaw A; Shaw JA; Zimmermann BG; ; ; Swanton C
    Nature; 2017 Apr; 545(7655):446-451. PubMed ID: 28445469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
    Abbosh C; Frankell AM; Harrison T; Kisistok J; Garnett A; Johnson L; Veeriah S; Moreau M; Chesh A; Chaunzwa TL; Weiss J; Schroeder MR; Ward S; Grigoriadis K; Shahpurwalla A; Litchfield K; Puttick C; Biswas D; Karasaki T; Black JRM; Martínez-Ruiz C; Bakir MA; Pich O; Watkins TBK; Lim EL; Huebner A; Moore DA; Godin-Heymann N; L'Hernault A; Bye H; Odell A; Roberts P; Gomes F; Patel AJ; Manzano E; Hiley CT; Carey N; Riley J; Cook DE; Hodgson D; Stetson D; Barrett JC; Kortlever RM; Evan GI; Hackshaw A; Daber RD; Shaw JA; Aerts HJWL; Licon A; Stahl J; Jamal-Hanjani M; ; Birkbak NJ; McGranahan N; Swanton C
    Nature; 2023 Apr; 616(7957):553-562. PubMed ID: 37055640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
    Tan AC; Lai GGY; Saw SPL; Chua KLM; Takano A; Ong BH; Koh TPT; Jain A; Tan WL; Ng QS; Kanesvaran R; Rajasekaran T; Kalashnikova E; Renner D; Sudhaman S; Malhotra M; Sethi H; Liu MC; Aleshin A; Lim WT; Tan EH; Skanderup AJ; Ang MK; Tan DSW
    Cancer; 2024 May; 130(10):1758-1765. PubMed ID: 38422026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
    Bossé Y; Dasgupta A; Abadier M; Guthrie V; Song F; Saavedra Armero V; Gaudreault N; Orain M; Lamaze FC; Melton C; Nance T; Hung T; Hodgson D; Abbosh C; Joubert P
    Cancer Lett; 2024 Jul; 594():216984. PubMed ID: 38797230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
    Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
    Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
    Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 9. The evolution of non-small cell lung cancer metastases in TRACERx.
    Al Bakir M; Huebner A; Martínez-Ruiz C; Grigoriadis K; Watkins TBK; Pich O; Moore DA; Veeriah S; Ward S; Laycock J; Johnson D; Rowan A; Razaq M; Akther M; Naceur-Lombardelli C; Prymas P; Toncheva A; Hessey S; Dietzen M; Colliver E; Frankell AM; Bunkum A; Lim EL; Karasaki T; Abbosh C; Hiley CT; Hill MS; Cook DE; Wilson GA; Salgado R; Nye E; Stone RK; Fennell DA; Price G; Kerr KM; Naidu B; Middleton G; Summers Y; Lindsay CR; Blackhall FH; Cave J; Blyth KG; Nair A; Ahmed A; Taylor MN; Procter AJ; Falzon M; Lawrence D; Navani N; Thakrar RM; Janes SM; Papadatos-Pastos D; Forster MD; Lee SM; Ahmad T; Quezada SA; Peggs KS; Van Loo P; Dive C; Hackshaw A; Birkbak NJ; Zaccaria S; ; Jamal-Hanjani M; McGranahan N; Swanton C
    Nature; 2023 Apr; 616(7957):534-542. PubMed ID: 37046095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
    Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
    J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
    Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.
    Normanno N; Denis MG; Thress KS; Ratcliffe M; Reck M
    Oncotarget; 2017 Feb; 8(7):12501-12516. PubMed ID: 27980215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumour trail left in blood.
    Chi KR
    Nature; 2016 Apr; 532(7598):269-71. PubMed ID: 27075102
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of circulating-tumor DNA analysis in non-small cell lung cancer.
    Jiang T; Ren S; Zhou C
    Lung Cancer; 2015 Nov; 90(2):128-34. PubMed ID: 26415994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer.
    Wan R; Wang Z; Lee JJ; Wang S; Li Q; Tang F; Wang J; Sun Y; Bai H; Wang D; Zhao J; Duan J; Zhuo M; An T; Wu M; Chen Z; Yang Z; Wang J
    J Thorac Oncol; 2017 Sep; 12(9):1376-1387. PubMed ID: 28552765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
    J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
    Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
    Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
    Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer.
    Tian X; Liu X; Wang K; Wang R; Li Y; Qian K; Wang T; Zhao X; Liu L; Zhang PL; Xiong Y; Rui J; Chen R; Zhang Y
    Thorac Cancer; 2024 Apr; 15(10):797-807. PubMed ID: 38409945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.
    He J; Tan W; Tang X; Ma J
    Pathol Oncol Res; 2017 Apr; 23(2):307-315. PubMed ID: 27511219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 97.